Cargando…
IL-2 Signaling Axis Defects: How Many Faces?
CD25, Signal transducer and activator of transcription 5B (STAT5B) and Forkhead box P3 (FOXP3) are critical mediators of Interleukin-2 (IL-2) signaling pathway in regulatory T cells (Tregs). CD25 (i.e., IL-2 Receptor α) binds with high affinity to IL-2, activating STAT5B-mediated signaling that even...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282996/ https://www.ncbi.nlm.nih.gov/pubmed/34277517 http://dx.doi.org/10.3389/fped.2021.669298 |
_version_ | 1783723109093736448 |
---|---|
author | Consonni, Filippo Favre, Claudio Gambineri, Eleonora |
author_facet | Consonni, Filippo Favre, Claudio Gambineri, Eleonora |
author_sort | Consonni, Filippo |
collection | PubMed |
description | CD25, Signal transducer and activator of transcription 5B (STAT5B) and Forkhead box P3 (FOXP3) are critical mediators of Interleukin-2 (IL-2) signaling pathway in regulatory T cells (Tregs). CD25 (i.e., IL-2 Receptor α) binds with high affinity to IL-2, activating STAT5B-mediated signaling that eventually results in transcription of FOXP3, a master regulator of Treg function. Consequently, loss-of-function mutations in these proteins give rise to Treg disorders (i.e., Tregopathies) that clinically result in multiorgan autoimmunity. Immunodysregulation, Polyendocrinopathy Enteropathy X-linked (IPEX), due to mutations in FOXP3, has historically been the prototype of Tregopathies. This review describes current knowledge about defects in CD25, STAT5B, and FOXP3, highlighting that these disorders both share a common biological background and display comparable clinical features. However, specific phenotypes are associated with each of these syndromes, while certain laboratory findings could be helpful tools for clinicians, in order to achieve a prompt genetic diagnosis. Current treatment strategies will be outlined, keeping an eye on gene editing, an interesting therapeutic perspective that could definitely change the natural history of these disorders. |
format | Online Article Text |
id | pubmed-8282996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82829962021-07-17 IL-2 Signaling Axis Defects: How Many Faces? Consonni, Filippo Favre, Claudio Gambineri, Eleonora Front Pediatr Pediatrics CD25, Signal transducer and activator of transcription 5B (STAT5B) and Forkhead box P3 (FOXP3) are critical mediators of Interleukin-2 (IL-2) signaling pathway in regulatory T cells (Tregs). CD25 (i.e., IL-2 Receptor α) binds with high affinity to IL-2, activating STAT5B-mediated signaling that eventually results in transcription of FOXP3, a master regulator of Treg function. Consequently, loss-of-function mutations in these proteins give rise to Treg disorders (i.e., Tregopathies) that clinically result in multiorgan autoimmunity. Immunodysregulation, Polyendocrinopathy Enteropathy X-linked (IPEX), due to mutations in FOXP3, has historically been the prototype of Tregopathies. This review describes current knowledge about defects in CD25, STAT5B, and FOXP3, highlighting that these disorders both share a common biological background and display comparable clinical features. However, specific phenotypes are associated with each of these syndromes, while certain laboratory findings could be helpful tools for clinicians, in order to achieve a prompt genetic diagnosis. Current treatment strategies will be outlined, keeping an eye on gene editing, an interesting therapeutic perspective that could definitely change the natural history of these disorders. Frontiers Media S.A. 2021-07-02 /pmc/articles/PMC8282996/ /pubmed/34277517 http://dx.doi.org/10.3389/fped.2021.669298 Text en Copyright © 2021 Consonni, Favre and Gambineri. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Consonni, Filippo Favre, Claudio Gambineri, Eleonora IL-2 Signaling Axis Defects: How Many Faces? |
title | IL-2 Signaling Axis Defects: How Many Faces? |
title_full | IL-2 Signaling Axis Defects: How Many Faces? |
title_fullStr | IL-2 Signaling Axis Defects: How Many Faces? |
title_full_unstemmed | IL-2 Signaling Axis Defects: How Many Faces? |
title_short | IL-2 Signaling Axis Defects: How Many Faces? |
title_sort | il-2 signaling axis defects: how many faces? |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282996/ https://www.ncbi.nlm.nih.gov/pubmed/34277517 http://dx.doi.org/10.3389/fped.2021.669298 |
work_keys_str_mv | AT consonnifilippo il2signalingaxisdefectshowmanyfaces AT favreclaudio il2signalingaxisdefectshowmanyfaces AT gambinerieleonora il2signalingaxisdefectshowmanyfaces |